AcelRx Pharmaceuticals (ACRX) Osake Kurssi
AcelRx Pharmaceuticals Kurssi
AcelRx Pharmaceuticalsn liikevaihto on supistunut 4,1 % vuodessa viimeisten 12 vuoden aikana 651 000,00 USD:een. AcelRx Pharmaceuticalsn nettomarginaali on nyt −1 580,2 %, noussut −2 325,9 %:sta muutama vuosi sitten. 8 analyytikosta 7 suosittaa ostoa — kokonaiskonsensus on Osta.
AcelRx Pharmaceuticals osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
AcelRx Pharmaceuticals liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset AcelRx Pharmaceuticals -osakkeesta
The business model of AcelRx Pharmaceuticals Inc. revolves around the development and commercialization of innovative therapies for acute pain management. As a specialty pharmaceutical company, AcelRx focuses on designing and delivering precise, non-invasive treatment options to improve patient outcomes. With a particular emphasis on the hospital setting, AcelRx aims to address the unmet needs of healthcare professionals and patients by providing advanced, user-friendly medication delivery systems. By leveraging its proprietary platform technology, AcelRx develops and markets novel products that enhance pain management and sedation practices, ultimately enhancing patient care and discomfort alleviation.
AcelRx Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of AcelRx Pharmaceuticals Inc in the market are companies such as Pfizer Inc., Johnson & Johnson, and Teva Pharmaceutical Industries Ltd. These companies compete with AcelRx Pharmaceuticals Inc in the field of innovative pharmaceutical products and solutions. While AcelRx Pharmaceuticals Inc is known for its specialized focus on developing and commercializing therapies for acute pain management, these competitors have a broad portfolio of pharmaceutical offerings in various therapeutic areas. As the market continues to evolve, AcelRx Pharmaceuticals Inc faces competition from these established players, stimulating innovation and driving advancements in the pharmaceutical industry.
AcelRx Pharmaceuticals Inc is a biopharmaceutical company based in Redwood City, California. Founded in 2005, AcelRx is focused on the development and commercialization of innovative therapies for the treatment of acute pain. The company specializes in developing solutions that enhance the safety, efficacy, and convenience of acute pain management. AcelRx has an extensive portfolio of products, including its flagship product, DSUVIA® (sufentanil sublingual tablet), which was approved by the U.S. FDA in 2018 for the management of acute pain in a medically supervised setting. With a commitment to advancing pain management options, AcelRx Pharmaceuticals Inc is dedicated to improving the lives of patients worldwide.
AcelRx Pharmaceuticals Inc has achieved significant milestones in its development. The company successfully gained FDA approval for their innovative drug Dsuvia, which offers a non-invasive pain relief method for patients. Additionally, AcelRx Pharmaceuticals Inc has expanded its market presence by partnering with major healthcare organizations, enabling wider distribution of their products. The company has also shown progress in clinical trials, consistently meeting important endpoints and showcasing the effectiveness of their therapeutics. AcelRx Pharmaceuticals Inc's commitment to innovation and their track record of achievements have positioned them as a leader in the pharmaceutical industry.
AcelRx Pharmaceuticals Inc is primarily present in the United States.
AcelRx Pharmaceuticals Inc represents a strong commitment to excellence, innovation, and patient care. With a focus on developing and delivering advanced therapies, AcelRx Pharmaceuticals Inc strives to improve the lives of patients suffering from acute pain. The company's corporate philosophy is guided by a dedication to ethics, integrity, and continuous improvement. By leveraging cutting-edge technologies and scientific expertise, AcelRx Pharmaceuticals Inc aims to provide safe and effective treatment options. As leaders in the pharmaceutical industry, their patient-centric approach and dedication to research and development make them a trusted choice for healthcare professionals and patients alike.
8 analyytikkoa arvioi tällä hetkellä AcelRx Pharmaceuticals-osaketta: 7 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat AcelRx Pharmaceuticals-yhtiöltä 12,58 M USD liikevaihtoa ja −0,58 USD osakekohtaista tulosta.
AcelRx Pharmaceuticals-osake (ACRX) on listattuna 3 pörssissä, muun muassa: NASDAQ (ACRX), Frankfurt (R5X.F), München (R5X.MU).
AcelRx Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative pain treatment solutions. The company is headquartered in California, USA and was founded in 2005.
odotettu liikevaihto AcelRx Pharmaceuticals on 12,58 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto AcelRx Pharmaceuticals on −9,77 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
P/E-suhdetta ei voida laskea AcelRx Pharmaceuticals:lle tällä hetkellä.
P/S-suhdetta ei voida laskea AcelRx Pharmaceuticals:lle tällä hetkellä.
AcelRx Pharmaceuticals:n Eulpool-laatuscore on 4/10.
AcelRx Pharmaceuticals:n ISIN on US00444T1007. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
AcelRx Pharmaceuticals:n WKN on A1H64B. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
AcelRx Pharmaceuticals:n ticker on ACRX. Tämä pörssinoteeraus käytetään AcelRx Pharmaceuticals-osakkeiden kauppaan pörssissä.
AcelRx Pharmaceuticals osake
AcelRx Pharmaceuticals vertaisryhmä
AcelRx Pharmaceuticals Ticker
AcelRx Pharmaceuticals FIGI
Kaikki tunnusluvut ja syvällinen analyysi AcelRx Pharmaceuticals:sta
Meidän osakeanalyysimme AcelRx Pharmaceuticals-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut AcelRx Pharmaceuticals:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: